Last updated: February 23, 2026
What is the Product and How Does It Market?
The drug associated with NDC 23155-0875 is Vibativ (telavancin), an antibiotic used primarily for complicated skin and skin structure infections. Approved by the FDA in 2013, Telavancin is marketed by Fresenius Kabi. It functions by inhibiting bacterial cell wall synthesis, targeting Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).
Vibativ faces an increasingly competitive landscape with newer antibiotics and the rise of antimicrobial resistance. The drug’s market penetration is limited by existing generic alternatives, safety concerns, and clinician prescribing patterns.
Current Market Size and Trends
Market Penetration and Sales Data
- 2021 global sales: Estimated at USD 40 million.
- US market share (2021): Approximately 50% of the global sales.
- Prescription volume: About 10,000 annual prescriptions in the US.
- Pricing: In 2022, the list price per vial was USD 3,850, with actual prices often lower due to discounts and rebates.
Competitive Landscape
| Drug Name |
Class |
Approval Year |
Key Features |
| Vancomycin |
Glycopeptide |
1958 |
Widely used; generic, low cost |
| Dalbavancin |
Lipoglycopeptide |
2014 |
Long half-life, single-dose potential |
| Oritavancin |
Lipoglycopeptide |
2014 |
Weekly dosing, high efficacy |
| Telavancin (Vibativ) |
Lipoglycopeptide |
2013 |
Binds with integrins, needs monitoring for adverse effects |
Market share remains limited due to safety issues like nephrotoxicity and metallic taste, which result in cautious prescribing.
Pricing Strategy and Projections
Historical Price Trends
- 2013–2017: Static list prices at around USD 3,850 per vial.
- 2018–2022: Slight reductions due to insurance negotiations; average net price approximately USD 3,200–USD 3,500.
Influencing Factors for Price Projection
- Generics: No generic version exists as of 2023, supporting premium pricing.
- Market competition: Introduction of newer agents with better safety profiles may pressure prices.
- Reimbursement policies: CMS and private insurers' policies influence actual sales volume and net prices.
Future Price Trends (2023–2028)
| Year |
Estimated List Price Per Vial |
Rationale |
| 2023 |
USD 3,400–USD 3,850 |
Stable due to lack of generics |
| 2024 |
USD 3,300–USD 3,850 |
Slight pressure from competitors |
| 2025 |
USD 3,200–USD 3,700 |
Increased competition potential |
| 2026 |
USD 3,200–USD 3,600 |
Market consolidation on safety |
| 2027 |
USD 3,100–USD 3,500 |
Generic options unlikely |
| 2028 |
USD 3,000–USD 3,500 |
Possible price stabilization |
Net prices after discounts are estimated to decline by 10–15% over five years, assuming continued safety concerns and competition.
Revenue Projections (2023–2028)
Assuming annual prescription volumes increase modestly from 10,000 to 15,000 prescriptions:
| Year |
Prescriptions |
Average Net Price (USD) |
Estimated Revenue (USD millions) |
| 2023 |
10,000 |
3,300 |
33 |
| 2024 |
11,000 |
3,250 |
36 |
| 2025 |
12,000 |
3,200 |
38 |
| 2026 |
13,000 |
3,150 |
41 |
| 2027 |
14,000 |
3,100 |
43 |
| 2028 |
15,000 |
3,000 |
45 |
Drivers and Risks
Drivers
- Prescribing in resistant infections.
- Lack of generic competition.
- Increasing antimicrobial stewardship in hospitals.
Risks
- Prescriber shift to newer drugs with better safety.
- Regulatory restrictions on use.
- Cost-containment measures reducing reimbursement.
Key Takeaways
- NDC 23155-0875 (Vibativ) maintains a stable market with limited growth potential due to safety concerns and competition.
- Price stability is expected over the next five years, with slight declines driven by insurance negotiations and emerging competitors.
- Future revenue depends on prescription volume growth and market acceptance amid safety and efficacy considerations.
FAQs
Q1: How does Vibativ compare price-wise to similar antibiotics?
A1: Its list price per vial (USD 3,850) exceeds older antibiotics like vancomycin by approximately USD 2,000 but aligns closely with newer lipoglycopeptides such as dalbavancin.
Q2: What are the primary factors influencing Vibativ's sales growth?
A2: Prescriptions driven by resistant infections, clinician preference, safety profile, and formulary inclusion.
Q3: Who are the main competitors?
A3: Vancomycin, dalbavancin, oritavancin, and newer agents approved for similar indications.
Q4: What is the patent status?
A4: No patent barriers exist; the drug is protected under market exclusivity until approximately 2030.
Q5: Are there policy changes likely to affect prices?
A5: Reimbursement reforms and antimicrobial stewardship initiatives could further pressure prices and sales volumes.
References
- U.S. Food and Drug Administration. (2013). Vibativ (telavancin) approval letter. https://www.fda.gov
- IQVIA. (2022). Prescription drug sales data.
- Centers for Medicare & Medicaid Services. (2022). Hospital formularies and coverage data.
- FDA. (2020). Antimicrobial Drug Approvals.
- Pharma intelligence. (2023). Market reports.
